Novo Nordisk pipeline at a glance (March 2026)
About the Novo Nordisk clinical program
Novo Nordisk has become one of the most valuable pharmaceutical companies in the world on the strength of its GLP-1 receptor agonist franchise. Ozempic (semaglutide injection) and Rybelsus (semaglutide oral) for type 2 diabetes, and Wegovy (semaglutide 2.4 mg) for obesity, represent a paradigm shift in metabolic disease treatment. The SELECT cardiovascular outcomes trial demonstrated that semaglutide reduces major cardiovascular events in overweight/obese patients without diabetes — transforming the obesity indication from cosmetic to cardiovascular risk reduction. Novo Nordisk's next-generation pipeline includes cagrilintide (amylin analogue), oral GLP-1/GIP combinations, and the GLP-1/GIP/glucagon tri-agonist CagriSema. In rare disease, Novo's Factor VIII (Alhemo), Sogroya (growth hormone), and mim8 (bispecific FVIII mimetic for hemophilia) are advancing through late-stage trials.
Key therapeutic areas
- Diabetes (GLP-1, basal insulin, SGLT2)
- Obesity / metabolic disease (semaglutide, dual agonists)
- Cardiovascular outcomes (MACE reduction)
- Rare hematology (hemophilia, rare bleeding disorders)
- Growth disorders / endocrinology
Key pipeline programs
- Ozempic/Wegovy/Rybelsus (semaglutide) — GLP-1 RA, T2D/obesity/CV
- CagriSema — cagrilintide/semaglutide combo, obesity
- Awiqli (once-weekly insulin icodec) — ultra-long-acting basal insulin
- Mim8 — bispecific FVIII mimetic, hemophilia A
- Alhemo (marstacimab) — anti-TFPI, rare bleeding disorders
- IcoSema — insulin icodec/semaglutide fixed-ratio combo
Monitor the Novo Nordisk pipeline daily
Get alerts when Novo Nordisk registers new trials or updates existing protocols. Free 14-day trial — no credit card required.
Start Monitoring FreeTop Novo Nordisk trial indications
| Condition / Indication | Trials |
|---|---|
| ["Diabetes Mellitus, Type 2"] | 16 |
| ["Obesity"] | 14 |
| ["Overweight", "Obesity"] | 10 |
| ["Type 2 Diabetes"] | 4 |
| ["Diabetes Mellitus, Type 1"] | 4 |
| ["Obesity", "Overweight"] | 3 |
| ["Haemophilia A"] | 3 |
| ["Heart Failure"] | 3 |
Why monitor Novo Nordisk's clinical trial activity
Novo Nordisk's GLP-1 expansion trials — including semaglutide in NASH/MASH, heart failure, sleep apnea, CKD, and addiction — are generating the highest search interest of any pharma pipeline in 2026. Their next-generation obesity combination trials (CagriSema vs. tirzepatide) are among the most watched competitive programs across pharma BD and investor audiences.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Novo Nordisk's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.
How DataLookout tracks Novo Nordisk trials
- Sponsor normalization: Novo Nordisk may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Novo Nordisk pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Start Free TrialFrequently asked questions
What GLP-1 programs is Novo Nordisk currently trialing?
Novo Nordisk's GLP-1 pipeline extends far beyond diabetes and obesity. Active programs include semaglutide in NASH/MASH (liver disease), heart failure with preserved ejection fraction, obstructive sleep apnea, chronic kidney disease, and alcohol use disorder. Their CagriSema (cagrilintide + semaglutide) combination targets superior weight loss over semaglutide alone, competing with Eli Lilly's tirzepatide.
How many Novo Nordisk trials are currently recruiting?
Based on current ClinicalTrials.gov data, 25 Novo Nordisk-sponsored trials are actively recruiting patients across diabetes, obesity, cardiovascular, rare disease, and other therapeutic areas.
Can DataLookout alert me to new Novo Nordisk obesity or diabetes trials?
Yes. Create a watchlist combining Novo Nordisk as the sponsor with indication keywords — obesity, GLP-1, semaglutide, or specific indications like MASH or heart failure. DataLookout delivers daily alerts on new trial registrations and protocol updates including enrollment openings.